EMA Authorised: Ceplene (histamine dihydrochloride) — Laboratoires Delbert

View source ↗

Summary

Authorised status for Ceplene (histamine dihydrochloride) for acute myeloid leukemia/therapy by Laboratoires Delbert in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Ceplene (histamine dihydrochloride)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myeloid, Acute. MAH: Laboratoires Delbert. Decision date: 09/09/2022